Clinical Study
Platelet Counts and Platelet Activation Markers in Obese Subjects
Table 4
Clinical data, laboratory findings, and platelet activation markers for subjects in
the platelet activation analysis.
| | Nonobese | Obese | P-value |
| | n | 35 | 30 | — | | Age (years) | 43 ± 12 | 41 ± 13 | .2 | | Body mass index (kg/m2) | 24 ± 2.7 | 41 ± 7.7 | <.0001 | | Waist circumference (cm) | 83 ± 12 | 120 ± 14 | <.0001 | | Hip circumference (cm) | 96 ± 6 | 131 ± 19 | <.0001 | | Waist/hip ratio | 0.86 ± 0.13 | 0.93 ± 0.15 | .06 | | Blood glucose (mg/dl) | 82 ± 8 | 105 ± 26 | .003 | | HDL cholesterol (mg/dl) | 62 ±17 | 46 ± 12 | <.0001 | | Triglyceride levels (mg/dl) | 119 ± 63 | 170 ± 87 | .01 | | Total cholesterol (mg/dl) | 232 ± 49 | 216 ± 47 | .2 | | LDL cholesterol (mg/dl) | 148 ± 47 | 136 ± 41 | .3 | | Platelet count (/L) | 259 ± 55 | 263 ± 55 | .7 | | Platelet activation
markers (MFI, range given in parentheses) | | PAC-1
binding | (1.8–24.6) | (1.7–22.7) | .09 | | P-selectin (CD-62p) | (1.3–4.4) | (1.5–3.6) | .3 | | Annexin-V binding | (2.1–12.2) | (2.4–8.0) | .15 |
|
|
HDL = high-density lipoprotein;
LDL = low-density lipoprotein; MFI = mean fluorescence intensity.
|
